The intriguing story that went viral online in March 2026 attracted significant global attention, showing how a determined individual combined his data expertise with cutting-edge AI tools to achieve what was previously thought impossible for a private citizen. Australian AI and data analytics expert, Paul Conyngham, refused to accept a terminal diagnosis for his rescue dog, Rosie, who had aggressive mast cell cancer and was only expected to live a few months despite conventional chemotherapy. The owner cried, “She is my best friend. Now it is my turn to fight her.”
Paul spent $3000 (AUD) at the UNSW Ramaciotti Center for Genomics to sequence Rossi’s healthy and tumor DNA, yielding approximately 300GB of genetic data. He used ChatGPT as a research assistant to create a “plan of attack”, research immunotherapy, and draft the complex 100-page ethics application required for the administration of an experimental drug in Australia.
technological breakthrough
Paul used Google DeepMind’s AlphaFold to model the 3D structure of Rosie’s mutant protein. They compared healthy and tumor DNA to pinpoint mutations and used their own machine-learning algorithms to identify seven interactions that would likely trigger an immune response. Next, they collaborated with the UNSW RNA Institute to synthesize a personalized mRNA vaccine based on their data—the first time such a vaccine had been designed for a dog by a non-scientist. The vaccine caused a significant reduction in Rosie’s primary tumor; His mobility and energy levels returned, allowing him to run and play again.
Although not a complete cure, treatment has transformed the terminal condition into a manageable one. Paul is currently working on a second round of vaccines to target the remaining tumor cells that were resistant to the first dose.
Ultimately, this discovery will pave the way for the democratization of personalized medicine, potentially making high-end cancer treatments more accessible and faster developed for both animals and humans.
